HK1057236A1 - Production of vaccines - Google Patents

Production of vaccines

Info

Publication number
HK1057236A1
HK1057236A1 HK04100143A HK04100143A HK1057236A1 HK 1057236 A1 HK1057236 A1 HK 1057236A1 HK 04100143 A HK04100143 A HK 04100143A HK 04100143 A HK04100143 A HK 04100143A HK 1057236 A1 HK1057236 A1 HK 1057236A1
Authority
HK
Hong Kong
Prior art keywords
virus
production
vaccines
viruses
human cells
Prior art date
Application number
HK04100143A
Other languages
English (en)
Inventor
Maria Grazia Pau
Alphonsus Gerardus C Uytdehaag
Govert Johan Schouten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1057236(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of HK1057236A1 publication Critical patent/HK1057236A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK04100143A 1999-11-26 2004-01-09 Production of vaccines HK1057236A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203983A EP1103610A1 (en) 1999-11-26 1999-11-26 Production of vaccines from immortalised mammalian cell lines
PCT/NL2000/000862 WO2001038362A2 (en) 1999-11-26 2000-11-24 Production of vaccines

Publications (1)

Publication Number Publication Date
HK1057236A1 true HK1057236A1 (en) 2004-03-19

Family

ID=8240914

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100143A HK1057236A1 (en) 1999-11-26 2004-01-09 Production of vaccines

Country Status (21)

Country Link
EP (3) EP1103610A1 (es)
JP (1) JP4331432B2 (es)
KR (2) KR20060107868A (es)
CN (1) CN1306033C (es)
AT (1) ATE286537T1 (es)
AU (2) AU775966B2 (es)
BR (1) BR0015846A (es)
CA (1) CA2392653C (es)
DE (1) DE60017234T3 (es)
DK (1) DK1108787T4 (es)
EA (1) EA006136B1 (es)
ES (1) ES2235770T5 (es)
HK (1) HK1057236A1 (es)
IL (2) IL149788A0 (es)
MX (1) MXPA02005237A (es)
NO (1) NO333527B1 (es)
NZ (1) NZ527942A (es)
PT (1) PT1108787E (es)
SI (1) SI1108787T2 (es)
WO (1) WO2001038362A2 (es)
ZA (1) ZA200204078B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7504248B2 (en) 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2435180C (en) 2001-01-19 2019-04-09 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002225509A1 (en) * 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
NZ533332A (en) 2001-12-17 2005-07-29 Crucell Holland B Efficient production of F(AB')2 fragments in mammalian cells
CA2477234C (en) 2002-02-21 2014-12-30 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
NZ538808A (en) * 2002-11-08 2008-03-28 Crucell Holland Bv Vaccines against west nile virus
AU2003299244A1 (en) * 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP4865539B2 (ja) 2003-05-09 2012-02-01 クルセル ホランド ベー ヴェー Ｅ１不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法
EP1670925B1 (en) 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN1930281A (zh) * 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
WO2006027698A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Decreasing potential iatrogenic risks associated with influenza vaccines
JP2006090864A (ja) * 2004-09-24 2006-04-06 Denka Seiken Co Ltd ワクチン中の特定成分の含量を求める方法
JP5085336B2 (ja) 2004-12-08 2012-11-28 メディミューン，エルエルシー インフルエンザワクチン組成物の製造方法
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ES2317517T5 (es) 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
DK1907536T3 (da) 2005-07-22 2010-07-19 Crucell Holland Bv Cellelinie til produktion af coronavira
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
DK2343362T4 (da) 2006-07-14 2024-07-08 Patheon Holdings I B V Forbedret fremgangsmåde til dyrkning af celler
JP5421250B2 (ja) * 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
WO2009074318A2 (en) * 2007-12-13 2009-06-18 Roche Diagnostics Gmbh Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
KR101639454B1 (ko) * 2008-07-15 2016-07-13 크루셀 홀란드 비.브이. Ｐｅｒ．ｃ6 세포의 배양에 대한 확장가능 방법 및 그 방법으로 생산된 산물
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
SG177655A1 (en) * 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
WO2011139717A1 (en) 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
CN102526720B (zh) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒疫苗的制备方法
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
CN102631673A (zh) * 2012-04-17 2012-08-15 金宇保灵生物药品有限公司 口蹄疫疫苗浓缩纯化方法
JP6742902B2 (ja) 2013-03-15 2020-08-19 ジェンザイム・コーポレーション 高密度細胞バンキングの方法
JP6760927B2 (ja) 2014-09-18 2020-09-23 ジェンザイム・コーポレーション 超高密度細胞バンキング方法
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
SI3233129T1 (sl) 2014-12-17 2020-07-31 Fundacion Para La Investigacion Medica Aplicada Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj
IL252917B2 (en) 2014-12-17 2023-10-01 Fundacion Para La Investig Medica Aplicada Vectors and vectors for gene therapy for use in the treatment of Wilson's disease
EP3764098B1 (en) * 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
KR20200015323A (ko) 2018-08-03 2020-02-12 에릭스바이오(주) 바이러스 치료 장치 또는 백신 제조 장치
CA3116098A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
US20210369870A1 (en) 2018-11-16 2021-12-02 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
WO2020226831A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP4192961A2 (en) 2020-08-06 2023-06-14 Fundacion para la Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CA3195052A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
AU2022378524A1 (en) 2021-10-28 2024-05-02 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547779A (en) * 1968-12-18 1970-12-15 Merck & Co Inc Process for producing purified concentrated influenza virus
US5192539A (en) * 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines

Also Published As

Publication number Publication date
DK1108787T3 (da) 2005-04-04
ES2235770T3 (es) 2005-07-16
EA200200604A1 (ru) 2002-12-26
ZA200204078B (en) 2003-08-22
EP1108787A2 (en) 2001-06-20
PT1108787E (pt) 2005-04-29
DK1108787T4 (da) 2009-04-14
NO20022500D0 (no) 2002-05-27
EP1514937A1 (en) 2005-03-16
CN1306033C (zh) 2007-03-21
DE60017234T2 (de) 2005-12-08
CA2392653C (en) 2011-03-29
JP2003516733A (ja) 2003-05-20
BR0015846A (pt) 2002-07-16
CN1433472A (zh) 2003-07-30
ATE286537T1 (de) 2005-01-15
EP1103610A1 (en) 2001-05-30
EP1108787A3 (en) 2001-08-29
NO333527B1 (no) 2013-07-01
CA2392653A1 (en) 2001-05-31
JP4331432B2 (ja) 2009-09-16
NZ527942A (en) 2004-07-30
IL149788A (en) 2010-12-30
DE60017234D1 (de) 2005-02-10
AU2004203642A1 (en) 2004-09-02
EA006136B1 (ru) 2005-10-27
EP1108787B1 (en) 2005-01-05
WO2001038362A2 (en) 2001-05-31
KR20020064910A (ko) 2002-08-10
MXPA02005237A (es) 2003-09-22
ES2235770T5 (es) 2009-05-01
NO20022500L (no) 2002-07-26
BRPI0015846B8 (es) 2021-05-25
AU775966B2 (en) 2004-08-19
KR100683374B1 (ko) 2007-02-15
SI1108787T1 (en) 2005-06-30
IL149788A0 (en) 2002-11-10
WO2001038362A3 (en) 2002-02-14
DE60017234T3 (de) 2009-07-09
SI1108787T2 (sl) 2009-06-30
EP1108787B2 (en) 2008-12-10
AU2557201A (en) 2001-06-04
KR20060107868A (ko) 2006-10-16
BRPI0015846B1 (pt) 2001-05-31

Similar Documents

Publication Publication Date Title
IL149788A (en) Production of vaccines
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
FR08C0046I2 (fr) Reconstitution in vitro de virus a arn de polarite negative segmentes
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
KR20120033334A (ko) 백신 제조를 위한 고역가 폴리오바이러스의 제조
JP2010138205A (ja) Ｍｄｃｋ細胞懸濁培養物において薬物または診断剤の活性成分を生成する方法
KR20050027164A (ko) 세포 배양물에서 바이러스의 증식 방법
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
MXPA05009096A (es) Metodo de cultivo celular libre de animal.
DE69327623D1 (de) Herstellungsmethode um multiple-sklerose-virus-assoziierte infizierte zellen zu erhalten
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
US3935066A (en) Cell lines
KR102696955B1 (ko) 무혈청 배지에서 부유배양이 가능한 신규한 Vero 세포주, 이의 제조 방법 및 상기 신규 세포주를 이용한 백신용 바이러스 제조 방법
JPH0998778A (ja) マレク病ワクチン
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
Igarashi A mutant of Chikungunya virus isolated from a line of Singh's Aedes albopictus cells by plaque formation on virus-sensitive cloned cells obtained from another Singh's A. albopictus cell line
Rafajko Routine establishment of serial lines of hamster embryo cells transformed by adenovirus type 12
SU764391A1 (ru) Способ культивировани вирусов
CA1064395A (en) Cell strain and virus culture
RU93048664A (ru) Способ суспензионного культивирования филовирусов в клеточных культурах на микроносителях
JP2016202147A (ja) 繊維材質支持体を用いたウイルス培養法
NL7709998A (en) Foetal canine lung diploid cell line - for virus cultures esp. for rabies vaccine prodn.
BG61384B1 (bg) метод за получаване на жива атенуирана клетъчно-културална ваксина против псевдочума по птиците

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201123